Head-To-Head Comparison: Xenetic Biosciences (NASDAQ:XBIO) versus Crescent Biopharma (NASDAQ:CBIO)

Xenetic Biosciences (NASDAQ:XBIO) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Profitability

This table compares Xenetic Biosciences and Crescent Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Crescent Biopharma	N/A	-103.44%	-88.19%

Institutional and Insider Ownership

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Xenetic Biosciences and Crescent Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1	0	0	0	1.00
Crescent Biopharma	1	0	4	1	2.83

Crescent Biopharma has a consensus price target of $29.00, indicating a potential upside of 56.89%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than Xenetic Biosciences.

Earnings and Valuation

This table compares Xenetic Biosciences and Crescent Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98 million	2.26	-$2.68 million	($1.20)	-2.45
Crescent Biopharma	$10.84 million	46.99	-$153.94 million	($10.91)	-1.69

Xenetic Biosciences has higher earnings, but lower revenue than Crescent Biopharma. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Xenetic Biosciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Summary

Crescent Biopharma beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.